Pfizer and others leading the pharmaceutical manufacturing with AI and Technology
The pharmaceutical industry has long embraced the power of modern technology to ensure the development and availability of safe and reliable medications. In today's fast-paced world, the need to swiftly bring new drugs and vaccines to market, especially in response to global health crises, has become more critical than ever before.
Normally, the process of discovering a potential breakthrough drug involves extensive laboratory investigations that span several years. However, there have been remarkable instances where artificial intelligence (AI) has accelerated this process significantly. For example, when Takeda Pharmaceutical Co., based in Japan, acquired an experimental psoriasis medication from a Boston firm for a staggering $4 billion, it was the result of an AI-driven selection process that took a mere six months. Such advancements highlight the transformative impact of AI in pharmaceutical manufacturing.
Let us delve deeper into AI and its applications in this industry, where cutting-edge technologies are revolutionizing the way medications are developed, manufactured, and brought to market.
How AI Helps in Pharmaceutical Breakthrough
AI is currently being applied in various ways within the pharmaceutical industry. One notable area is the improvement of manufacturing processes. Through the utilization of AI, processes can be enhanced in several ways. For instance, AI can facilitate quality control measures, reduce design time, minimize material waste, optimize production reuse, enable predictive maintenance, and much more.
AI is revolutionizing pharmaceutical manufacturing by boosting efficiency and productivity. AI-driven systems like CNC (Computer Numerical Control) Machine enable precise execution, while machine learning algorithms streamline processes, reducing waste and improving consistency. This leads to higher output and reduced material waste, benefiting the manufacturing ecosystem.
In drug discovery and design, AI plays a vital role in identifying targets, discovering new molecules, exploring multi-target options, repurposing drugs, and identifying biomarkers. Integration of AI expedites drug approval and market launch, potentially lowering costs and expanding treatment options. Personalized therapies can be developed by leveraging AI techniques and patient data, improving treatment efficacy.
AI is also transforming the processing of biomedical and clinical data. Algorithms efficiently analyze vast amounts of textual information, saving time for researchers. AI can collect and interpret diverse data sources, including handwritten notes and test results, facilitating expedited analysis and integration of data for further research.
How Pharmaceutical Manufacturers Leverage AI and Technology
As part of its digital transformation strategies, Pfizer leverages AI and data analytics to expedite drug discovery and improve operational efficiencies. With an estimated annual ICT spending of $3.6 billion in 2022, Pfizer prioritizes investment in software, ICT services, and hardware from vendors.
Detecting symptoms of rare diseases
Pfizer's successful initiative in utilizing predictive analytics and machine learning to identify symptoms of rare diseases, such as transthyretin amyloid cardiomyopathy (ATTR-CM), has significant implications for diagnostics. The study achieved an 87% accuracy in predicting heart failure patients with wtATTR-CM, showcasing the potential of AI in early disease detection. With a life expectancy of only two to three-and-a-half years if untreated, early diagnosis is crucial for progressive conditions like ATTR-CM. The development of the EstimATTR platform further supports diagnostic probability estimation for patients with heart failure. Pfizer's advancements in AI-driven diagnostics contribute to improved outcomes and public trust in the healthcare industry.
Pfizer Enhances Efficiency by Adopting Predictive Maintenance
Maintaining a secure and accurate data infrastructure is crucial for Pfizer to meet regulatory obligations. Pfizer has long relied on GE Digital's Proficy Historian to collect data from their manufacturing sites, controls, and utilities, consolidating them into a single operational technology (OT) dataset. Leveraging this data, they have undertaken efforts to optimize their operational performance.
"We are able to get a lot of benefit, a lot of reduced downtime, and a more reliable system." Kevin Callahan - Automation Engineer, Pfizer Inc.
Pfizer has successfully integrated real-time process data into their maintenance systems, transitioning from a traditional preventive maintenance approach to a more proactive predictive maintenance approach. This shift has significantly reduced downtime and provided the team with readily accessible data for analysis, leading to increased productivity and improved yield. By leveraging the power of predictive maintenance, Pfizer has achieved higher efficiency levels in their operations.
Moderna Leverage AI for Manufacturing and R&D
US pharmaceutical and biotechnology company Moderna has gained recognition for its rapid development of the COVID-19 vaccine. Leveraging the programmable nature of mRNA and its digital infrastructure, Moderna significantly accelerated its processes. By utilizing workflow automation, data capture, and AI, the company achieved unprecedented milestones, such as releasing the first clinical grade batch of the vaccine within 65 days of sequencing the virus. Moderna's drug design studio, supported by AI algorithms and hosted on AWS Fargate, allowed scientists to optimize mRNA constructs and streamline production. The company aims to continue leveraging AI technology, including IBM's generative AI model, to develop new vaccines and therapies for various diseases beyond COVID-19.
Moderna's success in rapidly developing the COVID-19 vaccine can be attributed to its innovative approach and advanced technological infrastructure. By initiating manufacturing while still conducting preclinical studies, the company maximized efficiency and minimized delays. The use of AI algorithms within their drug design studio further expedited processes, automating logistics decisions, quality control steps, and even assisting in the design of mRNA and DNA sequences. Moderna's adoption of AI-driven solutions allowed for the creation of thousands of unique mRNA constructs, including their COVID-19 vaccine.
Looking beyond the pandemic, Moderna plans to utilize AI technology to target diseases beyond COVID-19. Partnering with IBM, the company will leverage IBM's generative AI model, MoLFormer, to gain insights into potential mRNA medicines' characteristics. This collaboration aims to aid Moderna in designing a new class of vaccines and therapies. As the demand for COVID-19 vaccines and treatments slows down, Moderna seeks to harness AI's potential to continue advancing medical solutions and addressing other diseases in the post-pandemic era.
AstraZeneca Using AI to perform quick and precise image analysis
Their pathologists examine hundreds of tissue samples from their research every week. They examine them for disease and for biomarkers that could show which patients are most likely to react favorably to a given medication. Because it takes a lot of time, they are teaching AI systems to help pathologists analyze samples precisely and more quickly. This could reduce analysis time by more than 30%.
They used a strategy for one of their AI systems that was modeled after how certain self-driving cars perceive their surroundings. They programmed the AI system to evaluate tumor cells and immune cells for the presence of PD-L1, a biomarker that may be used to guide the selection of bladder cancer immunotherapy treatments. Research in other diseases is also being transformed by imaging and AI. A recent ambitious initiative to train deep neural networks to predict disease risk and associated biomarkers from retinal fundus images was undertaken by one of their biopharmaceutical research teams.
Novavax's utilization of AI in designing their COVID-influenza vaccine has yielded positive results in the Phase II trial
Artificial intelligence (AI) has played a crucial role in the development of Novavax's COVID-Influenza Combination (CIC) vaccine, aligning with the industry's growing reliance on AI in clinical trial design, according to GlobalData. By employing an innovative AI approach, Novavax achieved promising results in a Phase II trial for the CIC vaccine, demonstrating its safety, strong immune response, and comparability to other vaccines. With Phase III trials planned for later this year, Novavax aims to bring the first combined COVID-Influenza vaccine to market, leveraging the benefits of AI in dose selection and optimization.
Novavax utilized a design of experiments (DoE) approach and AI-driven response surface modeling to predict appropriate dosing combinations and observe antibody responses. By simultaneously adjusting doses for different strains, including SARS-CoV-2, the DoE software enabled precise fine-tuning and optimization of the CIC vaccine formulation. This AI integration in clinical trials not only accelerates processes but also reduces human errors and aids in decision-making.
Novavax's AI-driven trial design reflects a broader trend in the pharmaceutical industry, with companies like AstraZeneca, Moderna, and Pfizer also leveraging AI in their COVID-19 vaccine development. GlobalData reports a surge in AI-related patent activity, highlighting the increasing adoption of AI technologies in the pharmaceutical sector. These advancements have significantly contributed to the rapid vaccine response to the COVID-19 pandemic, improving the efficiency of mRNA sequence design and antigen detection.
Challenges and Future Outlook
Despite significant advancements, the use of AI and ML in drug discovery still faces limitations and challenges. Traditional laboratory work remains essential alongside AI implementation, as human clinical trials and testing are still required. Concerns about biases in AI algorithms and models also raise questions about the accuracy and reliability of generated clinical recommendations.
However, the future outlook for AI in pharmaceutical R&D is promising. There is a growing trend of integrating AI into R&D processes, with the potential to revolutionize the industry. Continued advancement and refinement of AI technologies are expected to have a profound impact, improving efficiency, reducing costs, and accelerating the drug discovery timeline. It is crucial to address the challenges and ensure the accuracy and safety of AI algorithms through ongoing research and development efforts.
Take action now to embrace the potential of AI in pharmaceutical research and development! Feel free to contact us!